Bicara Therapeutics Tech Stack
Clinical-stage immunotherapy company engineering dual-action antibodies for oncology
Bicara Therapeutics is a clinical-stage biotech company developing dual-action antibodies that combine targeted tumor delivery with immunomodulation. The hiring mix—heavily weighted toward data (6 roles), healthcare (3), and ops (3), with 11 directors and 4 VPs across a 51–200-person org—reflects the operational intensity of late-stage clinical programs. Active projects span investigator-initiated trials, real-world data initiatives, adaptive trial design, and clinical supply planning, while pain points center on vendor management, resource allocation, and integrating external lab data—typical friction points for companies scaling from discovery into registration-stage development.
Tech Stack 10 technologies
What Bicara Therapeutics Is Building
◆Challenges
- Vendor management
- Resource allocation across programs
- Integrating external lab data
- Meeting data management deadlines
- Meeting timelines and budgets
- Automation of repetitive tasks
- Preparing external landscape for product launch
- Building trust and credibility
- Regulatory disclosure for clinical milestones
- Late-stage analytical development challenges
▲Active Projects
- Us investigator-initiated trials
- Observational studies and registries
- Automation of repetitive tasks
- Real-world data initiatives
- Validation approaches for emerging technologies
- Build processes, sops, and governance frameworks
- Adaptive trial design for registration
- Case report form design and uat
- Clinical supply planning
- Ficerafusp alfa program
Hiring Activity
Department
Seniority
Notable leadership hires: Program Team Lead, Director Insights Analytics
